You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
浙江震元(000705.SZ)攜子公司共建震元生物 推進大健康領域新產品生產佈局
格隆匯 10-13 21:49

格隆匯10月13日丨浙江震元(000705.SZ)公佈,公司第十屆董事會2021年第四次臨時會議審議通過《關於設立浙江震元生物科技有限公司的議案》,同意公司與全資子公司浙江震元製藥有限公司(“震元製藥”)共同出資組建浙江震元生物科技有限公司(以工商核准名稱為準,以下簡稱“震元生物”),註冊資金3億元,雙方以貨幣或資產分期出資,於2023年12月31日之前到位,其中公司出資1.8億元,佔60%;震元製藥出資1.2億元,佔40%;授權公司經營班子做好具體工作。

震元生物獨立運營,有利於發揮公司在生物定向合成等領域的技術優勢和工業化生產經驗,加快推進公司在大健康領域新產品的生產佈局。

震元生物成立之後,將加快項目的實施。目前項目土地正在積極爭取中,後續將加快開展項目建設。在此期間,產業政策的調整、市場變化以及新建項目經營管理情況等因素的影響,都將影響子公司的運營結果,存在一定的風險。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account